Mark is the Queen's Lead of the £5M Medical Research Council-Cancer Research UK funded Stratified Medicine in Colorectal Cancer Consortium (S:CORT), a UK-wide consortium investigating novel precision medicine approaches in colorectal cancer(CRC). His international reputation in CRC was instrumental in his leading a Critical Gaps in Colorectal Cancer Research Initiative, recently published in the high impact factor journal Gut; this landmark publication has attracted significant global attention (his podcast had the most “hits” of any article in the journal) Mark is Queen's Lead of the Health Data Research UK Substantive Site, one of only 6 in the UK, which aims to drive innovative precision medicine and public health approaches through the use of Big Data. He is also national lead for Cancer Strategy for HDR-UK. Mark was co-chair of the Cancer Task Team of the Clinical Working Group of the Global Alliance for Genomics and Health (GA4GH), an international cooperative dedicated to effective and responsible sharing of genomic and clinical data. He has authored a number of key papers including a blueprint for cancer date sharing (published in Nature Medicine) and a road map/call to action for a Global Cancer Knowledge Network in the New England Journal of Medicine Mark has published over 180 papers in international peer review journals, including key papers in the highest impact journals (New Engl J Medicine, Lancet, Nature Medicine, Lancet Oncology, Cancer Discovery, Nature Comms, Gut etc). He is co-lead of an ambitious proposal to develop a Global Innovation Institute in Belfast which will include the One Health Innovation Centre (OHIC), the world’s first Health and Agri-Food Informatics Innovation Centre. Mark’s work has been recognised by a number of national/international awards including the Vander Molen Prize for Leukaemia Research, the Ely Lilly Prize, the St Lukes Medal for Cancer Research and the Graves Medal for Medical Research. He is frequently invited as a guest speaker to international conferences and sits on a number of high level boards/committees at European level including the European Alliance for Personalised Medicine, the Scientific Board of the European Cancer Patient Coalition and the European Cancer Organisation (ECCO) Oncopolicy Forum Mark has a strong commitment to patient-centred research/care and to addressing cancer inequalities. He was the architect of the European Cancer Patient's Bill of Rights (BoR), a catalyst for change and empowerment tool for cancer patients which he launched in the European Parliament on World Cancer Day 2014. The BoR has been adopted across Europe and led to the 70:35 Vision, 70% survival for all cancer patients in Europe by 2035 which was recently adopted by ECCO, the largest interdisciplinary cancer organisation in Europe. Mark’s advocacy work was instrumental in the recent decision to include boys in national UK HPV vaccination programmes. He is also committed to the provision of optimal pathology and laboratory medicine for citizens in resource-limited settings and was senior author of a recent paper in The Lancet as part of The Lancet Series on Pathology and Laboratory Medicine in Low- and Middle- Income Countries.
Roy A. Jensen, M.D. earned his bachelor’s degree in Biology and Chemistry from Pittsburg State University in 1980. He graduated from Vanderbilt University School of Medicine in 1984, and remained there to complete a residency in Anatomic Pathology and a Surgical Pathology fellowship under the direction of Dr. David L. Page. Following his clinical training he accepted a biotechnology training fellowship at the National Cancer Institute in the laboratory of Dr. Stuart Aaronson. He returned to Vanderbilt in 1991 and was appointed an assistant professor in the Departments of Pathology and Cell Biology. In 1993 Dr. Jensen was appointed as an investigator in the Vanderbilt-Ingram Cancer Center and assumed the management of the Human Tissue Acquisition and Pathology Shared Resource. Dr. Jensen was promoted to associate professor of Pathology and Cell Biology in 1996, and was appointed as an associate professor of Cancer Biology in 2001. In 2004, Dr. Jensen returned home to Kansas and was appointed the William R. Jewell, M.D. Distinguished Kansas Masonic Professor, the director of The University of Kansas Cancer Center, the director of the Kansas Masonic Cancer Research Institute, professor of Pathology and Laboratory Medicine, and professor of Anatomy and Cell Biology at the University of Kansas Medical Center. He also holds appointments as a professor in the Department of Molecular Biosciences at the University of Kansas-Lawrence and as professor in Cancer Biology at The University of Kansas Medical Center. Dr. Jensen is currently serving as president of the Association of American Cancer Institutes (AACI) and is a member of several scientific and professional societies including the American Association for Cancer Research, the American Association for the Advancement of Science, the American Society for Cell Biology, the American Society for Investigative Pathology, and the United States and Canadian Academy of Pathology. He currently has over 150 scientific publications and has lectured widely on the clinical and molecular aspects of breast cancer pathology. Dr. Jensen's research interests are focused on understanding the function of BRCA1 and BRCA2 and their role in breast and ovarian neoplasia; and in the characterization of premalignant breast disease both at the morphologic and molecular levels. His laboratory was instrumental in demonstrating the role of BRCA1 in the growth control of normal and malignant cells and in how loss of functional BRCA1 contributes to the development of breast cancer. Since becoming director of The University of Kansas Cancer Center in 2004, he has recruited a world-class leadership team and successfully led that team in achieving designation for The University of Kansas Cancer Center as a National Cancer Institute designated cancer center.
In 2009, she joined the Department of Pathology & Molecular Medicine at McMaster University and was promoted to associate professor in 2014. In 2019, she was promoted to tenure professor in the same department. The Bowdish lab focuses primarily on the effects of aging on the immune system, specifically macrophages. Her lab has been able to elucidate a mechanistic explanation for how aging alters myeloid cells and how these cells increase susceptibility to pneumococcal pneumonia. In 2017, the Bowdish lab demonstrated that age-associated gut microbe dysbiosis in mice increases age-associated inflammation. Bowdish currently holds an h-index score of 38. Bowdish's published works have received much media attention and continue to contribute more information regarding the interplay between the immune system, the gut microbiota, susceptibility to infection and aging.
He was elected by CAP Fellows as president-elect in the fall of 2017, during which time he has served on the Board of Governors and assumed various leadership duties. Godbey joined the Southeast Georgia Health System medical staff in 1983 as an obstetrician and gynecologist before transitioning to the practice of anatomic and clinical pathology. Godbey also currently serves as CEO and laboratory director of Southeastern Pathology Associates. An active member of the CAP for 25 years, Godbey was elected to his first full term as a member of the CAP Board of Governors in 2011, and held that position for two full terms, six years. He is also the recent chair of the Council on Government and Professional Affairs that oversees the direction of the organization’s legislative and regulatory advocacy efforts on behalf of patients, pathology, and medical laboratories—an issue he intends to focus on during his term as president-elect and later as president. Godbey has also served many other CAP Committee appointments, including vice-chair of the Council on Accreditation and Council on Membership and Professional Development; member of the Audit Committee, Conflicts of Interest Review Committee, Finance Committee, Investment Committee, Risk Management Committee, and SNOMED Terminology Solutions (STS) Venture Steering Committee (SVSC); and delegate, House of Delegates. He is a member of the Georgia Medicare Contractor Advisory Committee; a clinical faculty member of the Department of Pathology, Medical College of Georgia and College of Coastal Georgia; and board chair of the Camden Healthcare Network, a 300-member multispecialty group. He is also the co-founder and CEO of Southeast Energy/Tabby Power and trustee of Godbey Charitable Trust for the Godbey Appalachian Center. Professional positions held throughout his career have included the president of the Glynn County Medical Society, treasurer of the Glynn County Medical Society and member of the American Pathology Foundation Finance Committee, University of Georgia Honors Program Advisory Board, and State of Georgia Maternal Mortality Review Committee. Godbey is a member of the American College of Obstetricians and Gynecologists, American Pathology Foundation, American Society of Clinical Pathology, Association for Pathology Informatics, California Society of Pathologists, Chinese American Pathologists Association, Florida Society of Pathologists, Georgia Association of Pathologists, Georgia Obstetrics and Gynecology Society, Michigan Society of Pathologists, Pennsylvania Association of Pathologists, Texas Society of Pathologists and the United States and Canadian Academy of Pathology.
Professor of Pathology Mayo College of Medicine, Consulting Pathologist, Department of Pathology, Mayo Clinic, Jacksonville, Florida, Chair of College of American Pathologists Council on Scientific Affairs.College of American Pathologists (CAP)
Transplantation, Liver Disease, Quality Improvement, Surgical Pathology, anatomic pathology
Dr. Raouf E. Nakhleh has been practicing medicine for 29 years. Dr.Nakhleh graduated from the Wayne State University School of Medicine in 1985. He practices medicine in Jacksonville, FL, and specializes in Anatomic Pathology & Clinical Pathology. Dr. Nakhleh is affiliated with Mayo Clinic. His interest includes Transplantation, Liver disease, Quality Improvement, Laboratory Medicine, Pathology.
President-elect of the College of American Pathologists, Senior VP of Clinical Services, University Health System and Assistant Professor of Pathology and Laboratory Medicine, University of Texas Health, Long School of Medicine, San AntonioCollege of American Pathologists (CAP)
Pathology, Surgical Pathology, Gastrointestinal, Cytopathology
Emily E. Volk, MD, MBA, FCAP is the Senior Vice President, Clinical Services for University Health System in San Antonio, Texas. In addition, as a Clinical Assistant Professor of Pathology at the University of Texas-Health, she practices cytopathology and surgical pathology. Dr. Volk, board-certified in anatomic and clinical pathology with subspecialty certification in cytopathology, received her medical degree from the University of Missouri-Kansas City in 1993. Dr. Volk completed her pathology residency training with a certification year in Surgical Pathology with an emphasis in Gastrointestinal Pathology at the Cleveland Clinic Foundation in Cleveland, Ohio in 1998. Dr. Volk completed her fellowship in cytopathology at William Beaumont Hospital, Royal Oak, MI. Dr. Volk serves on the Executive Board of the Texas Society of Pathologists and is past president of the Michigan Society of Pathologists. At the College of American Pathologists, she serves on the Board of Governors and is the Vice-Chair of the Council and Government Professional Affairs. She chairs the Pathologists Quality Registry Committee for the CAP.
Dr. Edelmayer leads efforts to accelerate the scientific agenda of the Alzheimer’s Association through the creation and delivery of ongoing research education. She engages with more than 75 Alzheimer’s Association chapters across the country, ensuring that staff and the public are aware of the importance of medical research and the Association’s crucial role in advancing research to improve the lives of individuals living with dementia and their care partners. In addition, Dr. Edelmayer manages initiatives uniting researchers and clinicians with leaders of industry, regulatory agencies and the government on topics related to blood-based biomarker testing, use of digital health technologies and biotech approaches in studying dementia. Dr. Edelmayer has over 17 years of experience as a practicing scientist and educator. She spent more than six years as a pharmacologist in the Neuroscience and Immunology Discovery Divisions at Abbott and AbbVie, where she was recognized as an emerging scientific leader. As a senior scientist, she led a digital pathology team, conducted research and supported the development of clinical therapeutics in chronic inflammatory diseases of the nervous system and the skin. Dr. Edelmayer has lectured, published and led collaborations in areas of neurophysiology, inflammatory skin pathology and pain neurobiology. She completed her Ph.D. and postdoctoral training in medical pharmacology with a focus on neuropharmacology at the University of Arizona College of Medicine. Dr. Edelmayer holds a bachelor’s degree in neuroscience from the University of Pittsburgh, where she also completed a National Institute of Mental Health Research Fellowship.